|Bid||11.77 x 1800|
|Ask||13.10 x 800|
|Day's Range||12.35 - 13.49|
|52 Week Range||8.71 - 17.98|
|Beta (3Y Monthly)||2.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 13, 2019 - May 17, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.57|
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -26.09% and -81.60%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had a loss of 29 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
— 2018 was a Milestone Year for Dicerna Across a Variety of Fronts, Including Data Readouts for Primary Hyperoxaluria, Business Development Collaborations and a Successful Follow-O
NEW YORK, NY / ACCESSWIRE / March 11, 2019 / Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 8, 2019 at ...
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that the Company will release its fourth quarter and year end 2018 financial results after market close on Monday, March 11, 2019.
Dicerna Pharmaceuticals, Inc. (DRNA) (the “Company”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 238,000 shares of common stock to be distributed among six new employees, with a grant date of March 1, 2019 (the “Inducement Grant"). The stock options approved under the Inducement Grant were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $12.93, the fair market value on the grant date.
Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that Douglas M. Fambrough, Ph
Skyhawk signals progression toward the clinical stage with the hire of CMO Dr. Roberto Guerciolini, M.D., who brings deep experience as a clinician who took several of the earliest RNA targeting drugs ...
NEW YORK, Feb. 05, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
The Company anticipates human proof-of-concept data from the Phase 1 trial, which is known as DCR-HBVS-101, in the second half of 2019. “The dosing of the first human in the DCR-HBVS-101 trial brings us a step closer to the potential availability of an innovative therapy for patients with chronic hepatitis B, a serious liver infection that can lead to advanced hepatic disease or liver cancer if not treated effectively,” said Ralf Rosskamp, M.D., chief medical officer of Dicerna.
— J. Kevin Buchi Assumes Chairmanship Role and Industry Experts Marc Kozin and Anna Protopapas Join Dicerna Board —
Boehringer Ingelheim and Dicerna Pharmaceuticals (DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to a second hepatic disease target emerging from its research collaboration and license agreement with Dicerna. The collaboration, established in October 2017, aims to discover and develop novel GalXC™ RNAi therapeutics for the treatment of chronic liver diseases, with an initial focus on nonalcoholic steatohepatitis (NASH), a devastating disease for which there is no approved treatment.
CAMBRIDGE, Mass.-- -- Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that the Company will be added to the NASDAQ Biotechnology Index as part of the annual re-ranking, which will become effective prior to market open on Monday, December 24, 2018. The NASDAQ Biotechnology Index was launched in 1993 and is designed to ...
Dicerna Pharmaceuticals, Inc. (DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the closing of the global licensing and research collaboration between Dicerna and Eli Lilly and Company following clearance under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended. As previously announced on October 29, 2018, the companies entered into a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain. The companies will utilize Dicerna’s proprietary GalXC™ RNAi technology platform to progress new drug targets toward clinical development and commercialization.
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors endured a torrid quarter, which certainly propelled them to adjust their equity holdings so as to maintain the desired risk profile. As […]
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will host one-on-one investor meetings at Citi’s 2018 Global Healthcare Conference at the Lotte New York Palace Hotel in New York on Thursday, December 6, 2018.
With more and more genetic medicine companies going commercial, Leerink turned its attention to the sector this week. The Analyst Leerink’s Mani Foroohar initiated coverage of 10 genetic medicine companies ...